Figure 1
From: Molecular profiling of patient-derived breast cancer xenografts
Histology and IHC analysis of primary tumors and xenografts. Representative hematoxylin-eosin or hematoxylin-eosin-saffron stained sections of patient tumors and xenografts. A, luminal tumor HBC(x)-3. B, lobular tumor HBCx-19. C, triple-negative tumor HBC(x)-12A. D, HER2+ tumor HBCx-5. E, triple-negative tumor HBC(x)-10. F, triple-negative tumor HBC(x)-8. HBC, human breast cancer, HBC-n, HBC primary tumor n, HBCx-n, HBC xenograft tumor n, HER2+, human epidermal growth factor receptor 2 positive, IHC, immunohistochemistry.